NasdaqGS:ARWRBiotechs
Arrowhead Pharmaceuticals (ARWR) Is Up 23.5% After Strong Plozasiran Phase 3 Data in Severe Hypertriglyceridemia
Arrowhead Pharmaceuticals recently reported topline results from its global Phase 3 SHASTA-3 and SHASTA-4 trials, showing that plozasiran achieved large triglyceride reductions and significantly lowered acute pancreatitis events in patients with severe hypertriglyceridemia while maintaining a favorable safety profile.
Because plozasiran is already approved as REDEMPLO for familial chylomicronemia syndrome, these data give Arrowhead a basis to seek label expansion into the broader severe...